サンプル依頼リスト カート
  • English
  • Korean
  • Traditional Chinese
  • Simplified Chinese
デフォルト表紙
市場調査レポート
商品コード
1468127

多形性膠芽腫治療市場レポート：薬剤タイプ、投与経路、分子タイプ、流通チャネル、地域別、2024～2032年

Glioblastoma Multiforme Treatment Market Report by Drug Type, Route of Administration, Type of Molecule, Distribution Channel, and Region 2024-2032
出版日: | 発行: IMARC | ページ情報: 英文 138 Pages | 納期: 2～3営業日

● お客様のご希望に応じて、既存データの加工や未掲載情報（例：国別セグメント）の追加などの対応が可能です。　 詳細はお問い合わせください。

価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=156.58円
多形性膠芽腫治療市場レポート：薬剤タイプ、投与経路、分子タイプ、流通チャネル、地域別、2024～2032年
出版日: 2024年04月08日
発行: IMARC
ページ情報: 英文 138 Pages
納期: 2～3営業日
  • 全表示
  • 概要
  • 図表
  • 目次
概要

世界の多形性膠芽腫治療市場規模は2023年に21億米ドルに達しました。今後、IMARC Groupは、市場は2032年までに39億米ドルに達し、2024～2032年の間に6.7%の成長率（CAGR）を示すと予測しています。

グレードIVの星細胞腫としても知られる多形性膠芽腫は、悪性度IVの脳腫瘍であり、脳細胞内に急速に広がり、近隣の細胞にも感染する可能性があります。急速な細胞変性が特徴であるため、脳に大きな圧力がかかり、激しい頭痛や発作を引き起こします。正確な原因はまだわかっていないが、ターコット症候群のような稀な遺伝性疾患を含むいくつかの要因が原因であると考えられています。脳腫瘍の中でも致死率が高く、治療抵抗性であるため、診断後の生存期間は極めて短いです。現在の治療法は外科的切除、化学療法、放射線療法です。

腫瘍性疾患の有病率の増加や、世界の高齢者人口の増加は、市場成長を促進する主要要因の一つです。さらに、神経膠腫幹細胞の抵抗特性に対抗する高度な治療法の開拓も、市場成長にプラスの影響を与えています。さらに、がんや関連疾患に対する分子バイオテクノロジーや遺伝子治療の研究開発（R&D）活動の活発化が、さまざまな生物学的薬剤の開発を促進しています。これらの薬剤は、既存の治療法の副作用を軽減するのに役立っているため、患者の間で広く受け入れられています。さらに、医療インフラを改善するために世界各国の政府が行っている取り組みや、様々な治療法が利用可能であるという認識の高まりが、市場の展望をさらに明るいものにすると期待されています。

本レポートで扱う主要質問

  • 2023年の世界の多形性膠芽腫治療市場規模は？
  • 2024～2032年の世界の多形性膠芽腫治療市場の予想成長率は？
  • 世界の多形性膠芽腫治療市場を牽引する主要因は？
  • COVID-19が世界の多形性膠芽腫治療市場に与えた影響は？
  • 投与経路別の多形性膠芽腫治療の世界市場の内訳は？
  • 分子タイプ別の多形性膠芽腫治療の世界市場の内訳は？
  • 販売チャネル別の多形性膠芽腫治療の世界市場の内訳は？
  • 多形性膠芽腫治療の世界市場における主要地域は？
  • 世界の多形性膠芽腫治療市場における主要参入企業は？

目次

第1章 序文

第2章 調査範囲と調査手法

  • 調査目的
  • 利害関係者
  • データソース
    • 一次情報
    • 二次情報
  • 市場推定
    • ボトムアップアプローチ
    • トップダウンアプローチ
  • 調査手法

第3章 エグゼクティブサマリー

第4章 イントロダクション

  • 概要
  • 主要産業動向

第5章 多形性膠芽腫治療の世界市場

  • 市場概要
  • 市場実績
  • COVID-19の影響
  • 市場内訳：薬剤タイプ別
  • 市場内訳：投与経路別
  • 市場内訳：分子タイプ別
  • 市場内訳：流通チャネル別
  • 市場内訳：地域別
  • 市場予測

第6章 市場内訳：薬剤タイプ別

  • テモゾロミド
  • ベバシズマブ
  • カルムスチン
  • 放射線増感剤
  • その他

第7章 市場内訳：投与経路別

  • 経口剤
  • 非経口剤

第8章 市場内訳：分子タイプ別

  • 低分子
  • バイオロジクス

第9章 市場内訳：流通チャネル別

  • 病院
  • 薬局
  • その他

第10章 市場内訳：地域別

  • 北米
  • 欧州
  • アジア太平洋
  • 中東・アフリカ地域
  • ラテンアメリカ

第11章 SWOT分析

  • 概要
  • 強み
  • 弱み
  • 機会
  • 脅威

第12章 バリューチェーン分析

第13章 ポーターのファイブフォース分析

  • 概要
  • 買い手の交渉力
  • 供給企業の交渉力
  • 競合の程度
  • 新規参入業者の脅威
  • 代替品の脅威

第14章 価格分析

第15章 競合情勢

  • 市場構造
  • 主要企業
  • 主要企業のプロファイル
    • Sun Pharmaceutical Industries
    • Celldex Therapeutics
    • Pfizer
    • F. Hoffmann La Roche
    • Bristol-Myers Squibb
    • Teva Pharmaceuticals
    • Exelixis
    • Angiochem
    • Arbor Pharmaceuticals
図表

List of Figures

  • Figure 1: Global: Glioblastoma Multiforme Treatment Market: Major Drivers and Challenges
  • Figure 2: Global: Glioblastoma Multiforme Treatment Market: Sales Value (in Billion US$), 2018-2023
  • Figure 3: Global: Glioblastoma Multiforme Treatment Market: Breakup by Drug Type (in %), 2023
  • Figure 4: Global: Glioblastoma Multiforme Treatment Market: Breakup by Route of Administration (in %), 2023
  • Figure 5: Global: Glioblastoma Multiforme Treatment Market: Breakup by Type of Molecule (in %), 2023
  • Figure 6: Global: Glioblastoma Multiforme Treatment Market: Breakup by Distribution Channel (in %), 2023
  • Figure 7: Global: Glioblastoma Multiforme Treatment Market: Breakup by Region (in %), 2023
  • Figure 8: Global: Glioblastoma Multiforme Treatment Market Forecast: Sales Value (in Billion US$), 2024-2032
  • Figure 9: Global: Glioblastoma Multiforme Treatment Industry: SWOT Analysis
  • Figure 10: Global: Glioblastoma Multiforme Treatment Industry: Value Chain Analysis
  • Figure 11: Global: Glioblastoma Multiforme Treatment Industry: Porter's Five Forces Analysis
  • Figure 12: Global: Glioblastoma Multiforme Treatment (Temozolomide) Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 13: Global: Glioblastoma Multiforme Treatment (Temozolomide) Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 14: Global: Glioblastoma Multiforme Treatment (Bevacizumab) Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 15: Global: Glioblastoma Multiforme Treatment (Bevacizumab) Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 16: Global: Glioblastoma Multiforme Treatment (Carmustine) Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 17: Global: Glioblastoma Multiforme Treatment (Carmustine) Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 18: Global: Glioblastoma Multiforme Treatment (Radiosensitizers) Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 19: Global: Glioblastoma Multiforme Treatment (Radiosensitizers) Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 20: Global: Glioblastoma Multiforme Treatment (Other Drug Types) Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 21: Global: Glioblastoma Multiforme Treatment (Other Drug Types) Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 22: Global: Glioblastoma Multiforme Treatment (Oral) Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 23: Global: Glioblastoma Multiforme Treatment (Oral) Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 24: Global: Glioblastoma Multiforme Treatment (Parenteral) Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 25: Global: Glioblastoma Multiforme Treatment (Parenteral) Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 26: Global: Glioblastoma Multiforme Treatment (Small Molecule) Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 27: Global: Glioblastoma Multiforme Treatment (Small Molecule) Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 28: Global: Glioblastoma Multiforme Treatment (Biologics) Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 29: Global: Glioblastoma Multiforme Treatment (Biologics) Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 30: Global: Glioblastoma Multiforme Treatment Market: Sales through Hospitals (in Million US$), 2018 & 2023
  • Figure 31: Global: Glioblastoma Multiforme Treatment Market Forecast: Sales through Hospitals (in Million US$), 2024-2032
  • Figure 32: Global: Glioblastoma Multiforme Treatment Market: Sales through Pharmacies (in Million US$), 2018 & 2023
  • Figure 33: Global: Glioblastoma Multiforme Treatment Market Forecast: Sales through Pharmacies (in Million US$), 2024-2032
  • Figure 34: Global: Glioblastoma Multiforme Treatment Market: Sales through Other Distribution Channels (in Million US$), 2018 & 2023
  • Figure 35: Global: Glioblastoma Multiforme Treatment Market Forecast: Sales through Other Distribution Channels (in Million US$), 2024-2032
  • Figure 36: North America: Glioblastoma Multiforme Treatment Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 37: North America: Glioblastoma Multiforme Treatment Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 38: Europe: Glioblastoma Multiforme Treatment Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 39: Europe: Glioblastoma Multiforme Treatment Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 40: Asia Pacific: Glioblastoma Multiforme Treatment Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 41: Asia Pacific: Glioblastoma Multiforme Treatment Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 42: Middle East and Africa: Glioblastoma Multiforme Treatment Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 43: Middle East and Africa: Glioblastoma Multiforme Treatment Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 44: Latin America: Glioblastoma Multiforme Treatment Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 45: Latin America: Glioblastoma Multiforme Treatment Market Forecast: Sales Value (in Million US$), 2024-2032

List of Tables

  • Table 1: Global: Glioblastoma Multiforme Treatment Market: Key Industry Highlights, 2023 and 2032
  • Table 2: Global: Glioblastoma Multiforme Treatment Market Forecast: Breakup by Drug Type (in Million US$), 2024-2032
  • Table 3: Global: Glioblastoma Multiforme Treatment Market Forecast: Breakup by Route of Administration (in Million US$), 2024-2032
  • Table 4: Global: Glioblastoma Multiforme Treatment Market Forecast: Breakup by Type of Molecule (in Million US$), 2024-2032
  • Table 5: Global: Glioblastoma Multiforme Treatment Market Forecast: Breakup by Distribution Channel (in Million US$), 2024-2032
  • Table 6: Global: Glioblastoma Multiforme Treatment Market Forecast: Breakup by Region (in Million US$), 2024-2032
  • Table 7: Global: Glioblastoma Multiforme Treatment Market: Competitive Structure
  • Table 8: Global: Glioblastoma Multiforme Treatment Market: Key Players
目次
Product Code: SR112024A1488

The global glioblastoma multiforme treatment market size reached US$ 2.1 Billion in 2023. Looking forward, IMARC Group expects the market to reach US$ 3.9 Billion by 2032, exhibiting a growth rate (CAGR) of 6.7% during 2024-2032.

Glioblastoma multiforme, also known as grade IV astrocytoma, is a malignant grade IV brain tumor that rapidly spreads within the brain cells and can also infect the nearby cells. Since it is characterized by rapid cell degeneration, it creates immense pressure on the brain resulting in severe headaches and seizures. Although the exact cause of the diseases is still unknown, several factors including rare hereditary disorders such as Turcot syndrome are believed to be its cause. It is one of the most lethal forms of brain cancer and is treatment-resistant in nature, wherein the patient has an extremely short survival period post-diagnosis. The current treatment procedure of the disease includes surgical resection, chemotherapy and radiation.

Increasing prevalence of oncological diseases and a growing geriatric population across the globe are among the key factors driving the market growth. Furthermore, the development of advanced treatment methods that counter the resistive properties of glioma stem cells is also positively influencing the market growth. Additionally, increasing research and development (R&D) activities in molecular biotechnology and gene therapy for cancer and related diseases have facilitated the development of various biological drugs. These drugs assist in diminishing the side-effects of the existing treatment methods, thus creating broader acceptance amongst patients. Moreover, initiatives undertaken by several governments across the globe to improve healthcare infrastructure, along with the rising awareness of the availability of various therapies, are further expected to create a positive outlook for the market.

Key Market Segmentation:

IMARC Group provides an analysis of the key trends in each sub-segment of the global glioblastoma multiforme treatment market report, along with forecasts at the global and regional level from 2024-2032. Our report has categorized the market based on drug type, route of administration, type of molecule, and distribution channel.

Breakup by Drug Type:

Temozolomide

Bevacizumab

Carmustine

Radiosensitizers

Others

Breakup by Route of Administration:

Oral

Parenteral

Breakup by Type of Molecule:

Small Molecule

Biologics

Breakup by Distribution Channel:

Hospitals

Pharmacies

Others

Breakup by Region:

North America

Europe

Asia Pacific

Middle East and Africa

Latin America

Competitive Landscape:

The report has also analysed the competitive landscape of the market with some of the key players being Sun Pharmaceutical Industries, Celldex Therapeutics, Pfizer, F. Hoffmann La Roche, Bristol-Myers Squibb, Teva Pharmaceuticals, Exelixis, Angiochem and Arbor Pharmaceuticals.

IMARC Group's latest report provides a deep insight into the global glioblastoma multiforme treatment market covering all its essential aspects. This ranges from macro overview of the market to micro details of the industry performance, recent trends, key market drivers and challenges, SWOT analysis, Porter's five forces analysis, value chain analysis, etc. This report is a must-read for entrepreneurs, investors, researchers, consultants, business strategists, and all those who have any kind of stake or are planning to foray into the glioblastoma multiforme treatment market in any manner.

Key Questions Answered in This Report

  • 1. What was the size of the global glioblastoma multiforme treatment market in 2023?
  • 2. What is the expected growth rate of the global glioblastoma multiforme treatment market during 2024-2032?
  • 3. What are the key factors driving the global glioblastoma multiforme treatment market?
  • 4. What has been the impact of COVID-19 on the global glioblastoma multiforme treatment market?
  • 5. What is the breakup of the global glioblastoma multiforme treatment market based on the route of administration?
  • 6. What is the breakup of the global glioblastoma multiforme treatment market based on the type of molecule?
  • 7. What is the breakup of the global glioblastoma multiforme treatment market based on the distribution channel?
  • 8. What are the key regions in the global glioblastoma multiforme treatment market?
  • 9. Who are the key players/companies in the global glioblastoma multiforme treatment market?

Table of Contents

1 Preface

2 Scope and Methodology

  • 2.1 Objectives of the Study
  • 2.2 Stakeholders
  • 2.3 Data Sources
    • 2.3.1 Primary Sources
    • 2.3.2 Secondary Sources
  • 2.4 Market Estimation
    • 2.4.1 Bottom-Up Approach
    • 2.4.2 Top-Down Approach
  • 2.5 Forecasting Methodology

3 Executive Summary

4 Introduction

  • 4.1 Overview
  • 4.2 Key Industry Trends

5 Global Glioblastoma Multiforme Treatment Market

  • 5.1 Market Overview
  • 5.2 Market Performance
  • 5.3 Impact of COVID-19
  • 5.4 Market Breakup by Drug Type
  • 5.5 Market Breakup by Route of Administration
  • 5.6 Market Breakup by Type of Molecule
  • 5.7 Market Breakup by Distribution Channel
  • 5.8 Market Breakup by Region
  • 5.9 Market Forecast

6 Market Breakup by Drug Type

  • 6.1 Temozolomide
    • 6.1.1 Market Trends
    • 6.1.2 Market Forecast
  • 6.2 Bevacizumab
    • 6.2.1 Market Trends
    • 6.2.2 Market Forecast
  • 6.3 Carmustine
    • 6.3.1 Market Trends
    • 6.3.2 Market Forecast
  • 6.4 Radiosensitizers
    • 6.4.1 Market Trends
    • 6.4.2 Market Forecast
  • 6.5 Others
    • 6.5.1 Market Trends
    • 6.5.2 Market Forecast

7 Market Breakup by Route of Administration

  • 7.1 Oral
    • 7.1.1 Market Trends
    • 7.1.2 Market Forecast
  • 7.2 Parenteral
    • 7.2.1 Market Trends
    • 7.2.2 Market Forecast

8 Market Breakup by Type of Molecule

  • 8.1 Small Molecule
    • 8.1.1 Market Trends
    • 8.1.2 Market Forecast
  • 8.2 Biologics
    • 8.2.1 Market Trends
    • 8.2.2 Market Forecast

9 Market Breakup by Distribution Channel

  • 9.1 Hospitals
    • 9.1.1 Market Trends
    • 9.1.2 Market Forecast
  • 9.2 Pharmacies
    • 9.2.1 Market Trends
    • 9.2.2 Market Forecast
  • 9.3 Others
    • 9.3.1 Market Trends
    • 9.3.2 Market Forecast

10 Market Breakup by Region

  • 10.1 North America
    • 10.1.1 Market Trends
    • 10.1.2 Market Forecast
  • 10.2 Europe
    • 10.2.1 Market Trends
    • 10.2.2 Market Forecast
  • 10.3 Asia Pacific
    • 10.3.1 Market Trends
    • 10.3.2 Market Forecast
  • 10.4 Middle East and Africa
    • 10.4.1 Market Trends
    • 10.4.2 Market Forecast
  • 10.5 Latin America
    • 10.5.1 Market Trends
    • 10.5.2 Market Forecast

11 SWOT Analysis

  • 11.1 Overview
  • 11.2 Strengths
  • 11.3 Weaknesses
  • 11.4 Opportunities
  • 11.5 Threats

12 Value Chain Analysis

13 Porters Five Forces Analysis

  • 13.1 Overview
  • 13.2 Bargaining Power of Buyers
  • 13.3 Bargaining Power of Suppliers
  • 13.4 Degree of Competition
  • 13.5 Threat of New Entrants
  • 13.6 Threat of Substitutes

14 Price Analysis

15 Competitive Landscape

  • 15.1 Market Structure
  • 15.2 Key Players
  • 15.3 Profiles of Key Players
    • 15.3.1 Sun Pharmaceutical Industries
    • 15.3.2 Celldex Therapeutics
    • 15.3.3 Pfizer
    • 15.3.4 F. Hoffmann La Roche
    • 15.3.5 Bristol-Myers Squibb
    • 15.3.6 Teva Pharmaceuticals
    • 15.3.7 Exelixis
    • 15.3.8 Angiochem
    • 15.3.9 Arbor Pharmaceuticals